Back to Search
Start Over
A New Investigational Perspective for Purines Against Glioblastoma Invasiveness.
- Source :
-
Current drug targets [Curr Drug Targets] 2018; Vol. 19 (16), pp. 1871-1881. - Publication Year :
- 2018
-
Abstract
- Background: Glioblastoma Multiforme (GBM) is the most common and lethal brain malignancy. Recent evidence suggests that the presence of stem-like cells (GSCs) inside the tumor with high self-renewal, resistance to chemotherapy and invasiveness/migration potential is associated with poor GBM prognosis. GSC aggressiveness seems to be linked to an important process involved in tumorigenesis and cancer metastasis called Epithelial-to-Mesenchymal Transition (EMT), which is responsible for several biochemical changes and the acquisition of a more mesenchymal phenotype by GSCs, that enhance their migration, invasiveness and resistance to apoptosis.<br />Objective: Since previous reports demonstrated that purines, interacting with their own receptors, exerted anti-tumor effects in GBM and derived cells, we tried to investigate the ability of these compounds to reduce tumor cell migration/invasion acting on EMT-associated genes/activators and/or signal pathways.<br />Methods: Search in the literature of relevant articles related to the objective.<br />Results: Papers examining the activity of purines on EMT signaling pathways/markers in GSCs are still few whereas literature is more abundant as for other kinds of tumors.<br />Conclusion: Considering the significance of EMT in GBM aggressiveness and the promising involvement of purines in this process, we think that further research in this regard may open the way towards a new therapeutic approach for the control of GBM invasiveness/recurrence.<br /> (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
- Subjects :
- Antineoplastic Agents therapeutic use
Brain Neoplasms pathology
Cell Movement drug effects
Clinical Trials as Topic
Epithelial-Mesenchymal Transition drug effects
Glioblastoma pathology
Humans
Molecular Targeted Therapy methods
Neoplasm Invasiveness prevention & control
Purinergic Antagonists therapeutic use
Purines pharmacology
Receptors, Purinergic metabolism
Signal Transduction drug effects
Treatment Outcome
Antineoplastic Agents pharmacology
Brain Neoplasms drug therapy
Glioblastoma drug therapy
Purinergic Antagonists pharmacology
Purines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5592
- Volume :
- 19
- Issue :
- 16
- Database :
- MEDLINE
- Journal :
- Current drug targets
- Publication Type :
- Academic Journal
- Accession number :
- 29484991
- Full Text :
- https://doi.org/10.2174/1389450119666180226123819